Total Payments
$336,879
2024 Payments
$74,610
Companies
30
Transactions
333
Medicare Patients
539
Medicare Billing
$137,827
Payment Breakdown by Category
Consulting$230,089 (68.3%)
Other$49,406 (14.7%)
Travel$30,045 (8.9%)
Research$18,941 (5.6%)
Food & Beverage$8,397 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $230,089 | 91 | 68.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,952 | 14 | 13.3% |
| Travel and Lodging | $30,045 | 63 | 8.9% |
| Unspecified | $18,941 | 23 | 5.6% |
| Food and Beverage | $8,397 | 139 | 2.5% |
| Honoraria | $4,225 | 2 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $228.66 | 1 | 0.1% |
Payments by Type
General
$317,937
310 transactions
Research
$18,941
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $48,351 | 67 | $0 (2024) |
| ADC Therapeutics America, Inc. | $36,662 | 44 | $0 (2024) |
| Genmab U.S., Inc. | $35,015 | 19 | $0 (2024) |
| Genentech, Inc. | $32,661 | 12 | $0 (2024) |
| Kite Pharma, Inc. | $26,193 | 23 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $21,409 | 18 | $0 (2024) |
| Genentech USA, Inc. | $20,855 | 25 | $0 (2024) |
| Incyte Corporation | $20,596 | 13 | $0 (2021) |
| F. Hoffmann-La Roche AG | $15,198 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $9,408 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74,610 | 76 | ABBVIE INC. ($11,659) |
| 2023 | $122,404 | 127 | Genmab U.S., Inc. ($33,450) |
| 2022 | $53,617 | 48 | ADC Therapeutics America, Inc. ($24,698) |
| 2021 | $13,547 | 11 | Genentech, Inc. ($4,620) |
| 2020 | $20,092 | 14 | Kite Pharma, Inc. ($4,980) |
| 2019 | $26,484 | 24 | Incyte Corporation ($10,859) |
| 2018 | $15,980 | 21 | Bayer HealthCare Pharmaceuticals Inc. ($7,544) |
| 2017 | $10,145 | 12 | Incyte Corporation ($6,352) |
All Payment Transactions
333 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $738.62 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $448.24 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $329.16 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $119.17 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,180.15 | General |
| 12/19/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/10/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $59.26 | General |
| 12/10/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $26.94 | General |
| 12/10/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $26.94 | General |
| 12/09/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $47.21 | General |
| Category: BioOncology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $32.98 | General |
| Category: Oncology | ||||||
| 12/09/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $31.20 | General |
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/08/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/07/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $34.49 | General |
| 12/06/2024 | ABBVIE INC. | — | — | In-kind items and services | $53.84 | Research |
| Study: A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin's Lymphoma | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $141.29 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Food and Beverage | In-kind items and services | $82.59 | General |
| Category: BioOncology | ||||||
| 11/01/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,480.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Obinutuzumab Gazyva Polatuzumab Vedotin Venetoclax GDC 0199 in RR FL DLBCL | F. Hoffmann-La Roche AG | $3,909 | 3 |
| CC-5013-MCL-004 | Celgene Corporation | $3,689 | 1 |
| Ph1b 2 TDB CHP Pola in NHL for dose escalation Ph1b followed by 1L DLBCL for expansion Ph2 | F. Hoffmann-La Roche AG | $2,769 | 1 |
| A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DCDT2980S in combination with rituximab or DCDS4501A in combination with rituximab in patients with relapsed or refractory B-cell non Hodgkin's lymphoma | F. Hoffmann-La Roche AG | $2,619 | 1 |
| Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | F. Hoffmann-La Roche AG | $2,339 | 7 |
| GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma | F. Hoffmann-La Roche AG | $1,749 | 2 |
| A PHASE IbII STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $1,265 | 4 |
| Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | F. Hoffmann-La Roche AG | $478.18 | 1 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | AbbVie Inc. | $54.10 | 1 |
| A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin's Lymphoma | ABBVIE INC. | $53.84 | 1 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 108 | 390 | $160,450 | $40,526 |
| 2022 | 4 | 106 | 242 | $52,577 | $18,970 |
| 2021 | 4 | 175 | 394 | $64,215 | $41,912 |
| 2020 | 4 | 150 | 426 | $85,917 | $36,419 |
Total Patients
539
Total Services
1,452
Medicare Billing
$137,827
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 214 | $92,912 | $20,137 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 145 | $55,100 | $17,290 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $7,241 | $1,971 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 18 | $5,196 | $1,127 | 21.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 92 | $27,932 | $7,689 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 40 | $7,296 | $4,305 | 59.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 57 | $7,112 | $3,810 | 53.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 53 | $10,237 | $3,165 | 30.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 87 | 284 | $48,848 | $32,629 | 66.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 82 | $9,840 | $6,437 | 65.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $4,368 | $2,164 | 49.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 14 | $1,159 | $681.69 | 58.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 88 | 256 | $44,032 | $23,157 | 52.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 112 | $32,060 | $8,847 | 27.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 43 | $5,145 | $2,625 | 51.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $4,680 | $1,789 | 38.2% |
About Dr. Tycel Phillips, M.D
Dr. Tycel Phillips, M.D is a Internal Medicine healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1568607653.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tycel Phillips, M.D has received a total of $336,879 in payments from pharmaceutical and medical device companies, with $74,610 received in 2024. These payments were reported across 333 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($230,089).
As a Medicare-enrolled provider, Phillips has provided services to 539 Medicare beneficiaries, totaling 1,452 services with total Medicare billing of $137,827. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Duarte, CA
- Active Since 12/04/2008
- Last Updated 05/04/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1568607653
Products in Payments
- Epkinly (Drug) $35,015
- VENCLEXTA (Drug) $23,671
- CALQUENCE (Drug) $21,937
- Yescarta (Drug) $14,376
- ADCETRIS (Biological) $9,177
- BRUKINSA (Drug) $8,546
- Aliqopa (Drug) $8,444
- POLIVY (Biological) $7,084
- Columvi (Biological) $6,726
- Rituxan (Biological) $5,205
- Imbruvica (Drug) $5,177
- Tecartus (Drug) $5,094
- JAYPIRCA (Drug) $3,732
- Tazverik (Drug) $3,724
- Revlimid (Drug) $3,689
- Non-Covered Product (Drug) $2,750
- Venclexta (Biological) $2,660
- Polivy (Biological) $2,391
- IMBRUVICA (Drug) $2,370
- EPKINLY (Drug) $2,207
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Duarte
Amrita Krishnan, Md, MD
Internal Medicine — Payments: $841,332
Internal Medicine $841,332
Dr. Daneng Li, M.d, M.D
Internal Medicine — Payments: $584,406
Internal Medicine $584,406
Alexey Danilov, M.d, M.D
Internal Medicine — Payments: $419,324
Internal Medicine $419,324
Marwan Fakih, Md, MD
Internal Medicine — Payments: $355,683
Internal Medicine $355,683
Haris Ali, M.d, M.D
Internal Medicine — Payments: $293,846
Internal Medicine $293,846
Dr. Tanya Siddiqi, M.d, M.D
Internal Medicine — Payments: $253,344
Internal Medicine $253,344